Generic clopidogrel–the medicines agency’s perspective
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
A number of generic products containing clopidogrel as the active substance have been marketed in Austria and the EU for some time. Due to different clopidogrel salt preparations and different indications, doubts arose as to whether the products could be considered as equivalent. The Austrian Federal Office for Safety in Health Care (BASG)/The Austrian Agency for Health and Food Safety (AGES PharmMed) considered this issue and reached the conclusion that the generic clopidogrel products were in principle equivalent to the originator product with regard to safety and efficacy.
Authors and Affiliations
Christoph Baumgärtel
Keywords
Related Articles
- EP ID EP355165
- DOI 10.5639/gabij.2012.0102.019
- Views 120
- Downloads 0
Biosimilar monoclonal antibodies approved for use in the EU
Two biosimilar TNF-alfa monoclonal antibody (mAb) products were approved for clinical use in the European Union on 10 September 2013, following a positive opinion by the Committee for Medicinal Products for Human Use (CH...
IAPO launched the Patient-Centred Healthcare Indicators Review
In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage o...
Perceptions of physicians from private medical centres in Malaysia about generic medicine usage: a qualitative study
Introduction: The healthcare sector is one of the most rapidly expanding and dynamic industries in the world. Pharmaceutical expenditure is now growing faster than other components of healthcare overheads. Globally, pres...
Why bioequivalence and unconditional interchangeability of generic drugs are not the same
The patents for a number of cornerstone immunosuppressive drugs used in the field of solid organ transplantation have expired. Generic formulations are now available and several professional societies and individual phys...
Weighing up the cost of switching to biosimilars
It is far from clear whether off-patent biological medicines can offer the same cost savings as those offered by off-patent non-biological (chemically derived) medicines, write a group of Brussels-based health economists...